Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 5

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) General Information

Description

An oral therapy approved in 51 countries worldwide, including member states of the European Union and the USA. The medication is for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) to reduce blood Phe levels in patients. It is a pharmaceutical formulation of BH4, the natural cofactor for the PAH enzyme, which stimulates activity of the residual PAH enzyme to metabolize Phe into tyrosine. It is to be used in conjunction with a Phe-restricted diet.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Other Business Products and Services
Primary Office
  • Darmstadt
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request a free trial

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request a free trial